Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

AIMS/HYPOTHESIS: Type 1 diabetes results from T cell mediated destruction of beta cells. We conducted a trial of antithymocyte globulin (ATG) in new-onset type 1 diabetes (the Study of Thymoglobulin to ARrest T1D [START] trial). Our goal was to evaluate the longer-term safety and efficacy of ATG in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetologia
Autors principals: Gitelman, Stephen E., Gottlieb, Peter A., Felner, Eric I., Willi, Steven M., Fisher, Lynda K., Moran, Antoinette, Gottschalk, Michael, Moore, Wayne V., Pinckney, Ashley, Keyes-Elstein, Lynette, Harris, Kristina M., Kanaparthi, Sai, Phippard, Deborah, Ding, Linna, Bluestone, Jeffrey A., Ehlers, Mario R.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869699/
https://ncbi.nlm.nih.gov/pubmed/27053235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-016-3917-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars